Privacy Policy
Signals Blog

Contributors

Categories

Cal Strode

Cal Strode is a communications consultant specializing in health, science, and innovation, with experience in these sectors across the UK, Canada, and U.S. Previously, he was the Manager, Communications at CCRM. Before that, he worked with the UK’s National Institute for Health Research (NIHR) Applied Research Collaboration North West Coast (ARC NWC) and UK Research & Innovation’s (UKRI) 3DBioNet network. He also has five years of public health communications experience, delivering national campaigns with measurable impact in the fields of mental and sexual health. With an interest in how effective communications can catalyze change, his undergraduate thesis on the topic won the European Public Relations Education and Research Association (EUPRERA) award, which led to him presenting his findings at EUPRERA’s congress in Brussels. Outside of work, he enjoys surfing and open-water swimming. Follow him on X @CalStrode.

Posts by: Cal


Peeling back the label: Is Right To Try just a repackaging of existing options?

Author: Cal Strode, 07/12/23

In 2017, Signals’ blog carnival focused on Right to Try (RTT) legislation – laws that allow patients with life-threatening conditions to ask drugmakers for medicines that have cleared some testing hurdles, but still haven’t been approved by the U.S. Food and Drug Administration (FDA). RTT legislation was first introduced in 2014, and Colorado was the first state to […]

ARM Sector Snapshot: Gene editing takes centre stage and 2023 approvals near

Author: Cal Strode, 05/18/23

Regular readers of Alliance for Regenerative Medicine (ARM) sector reports may have noticed that the organization is taking a new approach to sharing insights on the cell and gene therapy sector. In April, ARM launched a new format for distilling key data and trend insights. Let’s delve into the key highlights from April’s inaugural Sector […]

Counting iPSheep: Challenges keeping CGT leaders up at night

Author: Cal Strode, 04/27/23

The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K. Schneider, Head of Biopharma Excellence, who has held leadership roles with both Danish and UK regulatory agencies, […]

A new kind of influencer: Dr. Peter Zandstra on engineering cell fate decisions

Author: Cal Strode, 03/29/23

Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are developing technologies set to transform the lives of patients) and he’s the founding Director of the University of British […]

ARM’s “State of the Industry” update: Keeping up with the speed of science

Author: Cal Strode, 01/12/23

The Alliance for Regenerative Medicine (ARM) delivered its State of the Industry Briefing (#CGSOTI23) at Biotech Showcase, held January 9–11, 2023, in San Francisco, California. Tim Hunt, CEO, of the Alliance for Regenerative Medicine (ARM) kicked things off by outlining ARM’s role in convening the regenerative medicine (RM) sector. He spoke of ARM’s efforts to […]